归巢(生物学)
医学
不利影响
黑色素瘤
细胞
癌症研究
免疫学
肿瘤科
过继性细胞移植
T细胞
内科学
生物
免疫系统
生态学
遗传学
作者
Jelter Van Hoeck,Christian Vanhove,Stefaan C. De Smedt,Koen Raemdonck
标识
DOI:10.1016/j.drudis.2021.10.012
摘要
Adoptive T cell therapies (ACT) have demonstrated groundbreaking results in blood cancers and melanoma. Nevertheless, their significant cost, the occurrence of severe adverse events, and their poor performance in solid tumors are important hurdles hampering more widespread applicability. In vivo cell-tracking allows instantaneous and non-invasive monitoring of the distribution, tumor homing, persistence, and redistribution to other organs of infused T cells in patients. Furthermore, cell-tracking could aid in the clinical management of patients, allowing the detection of non-responders or severe adverse events at an early stage. This review provides a concise overview of the main principles and potential of cell-tracking, followed by a discussion of the clinically relevant labeling strategies and their application in ACT.
科研通智能强力驱动
Strongly Powered by AbleSci AI